CRSP – CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP

$45.75

Name : CRISPR Therapeutics AG

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $4,437,787,136.00

EPSttm : -4.73

CRISPR Therapeutics AG

$45.75

1.33%

$0.6

CRSP — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

18.26

Margin Of Safety %

Put/Call OI Ratio

0.48

EPS Next Q Diff

0.06

EPS Last/This Y

1.93

EPS This/Next Y

0.84

Price

45.21

Target Price

82.74

Analyst Recom

1.87

Performance Q

-16.37

Upside

-468.2%

Beta

1.9

Ticker: CRSP

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	CRSP	51.8	0.56	0.99	65547
2026-10-13	CRSP	50.12	0.56	1.34	66230
2026-10-14	CRSP	50.23	0.57	2.00	67603
2026-10-15	CRSP	51.53	0.56	0.43	67659
2026-10-16	CRSP	49.28	0.57	3.23	69742
2026-10-19	CRSP	50.04	0.56	0.26	56577
2026-10-20	CRSP	49.92	0.55	0.25	58024
2026-10-21	CRSP	50.51	0.54	0.18	59330
2026-10-22	CRSP	49.97	0.54	1.10	59751
2026-10-23	CRSP	49.37	0.54	0.41	60077
2026-10-26	CRSP	48.99	0.54	0.28	57960
2026-10-27	CRSP	51.48	0.53	0.38	58702
2026-10-28	CRSP	55.3	0.52	0.20	59741
2026-10-29	CRSP	54.27	0.51	0.27	60779
2026-10-30	CRSP	51.41	0.51	0.80	61016
2026-11-02	CRSP	49	0.51	0.35	58474
2026-11-03	CRSP	50.04	0.51	0.33	59581
2026-11-04	CRSP	51.79	0.51	0.12	61015
2026-11-05	CRSP	48.58	0.51	0.71	61757
2026-11-06	CRSP	50.07	0.50	0.46	61922
2026-11-09	CRSP	50.04	0.50	0.13	60428
2026-11-10	CRSP	45.15	0.48	1.23	62047
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	CRSP	51.53	10.0	-	-4.45
2026-10-13	CRSP	50.12	10.2	-	-4.45
2026-10-14	CRSP	50.22	10.0	-	-4.45
2026-10-15	CRSP	51.51	10.0	-	-4.45
2026-10-16	CRSP	49.28	9.4	-	-4.45
2026-10-19	CRSP	50.04	9.4	-	-4.45
2026-10-20	CRSP	50.04	9.4	-	-4.45
2026-10-21	CRSP	49.90	9.4	-	-4.45
2026-10-22	CRSP	49.97	9.4	-	-4.45
2026-10-23	CRSP	49.39	9.4	-	-4.45
2026-10-26	CRSP	49.01	9.4	-	-4.45
2026-10-27	CRSP	51.48	9.4	-	-4.45
2026-10-28	CRSP	54.08	9.4	-	-4.45
2026-10-29	CRSP	54.26	9.4	-	-4.45
2026-10-30	CRSP	51.40	9.4	-	-4.45
2026-11-02	CRSP	49.49	9.4	-	-4.45
2026-11-03	CRSP	49.99	9.4	-	-4.45
2026-11-04	CRSP	51.79	9.4	-	-4.57
2026-11-05	CRSP	48.57	9.4	-	-4.57
2026-11-06	CRSP	50.08	9.4	-	-4.52
2026-11-09	CRSP	50.06	9.4	-	-4.52
2026-11-10	CRSP	45.21	9.4	-	-4.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	CRSP	-0.43	-1.47	20.81
2026-10-13	CRSP	-0.43	-1.47	20.81
2026-10-14	CRSP	-0.43	-1.47	20.81
2026-10-15	CRSP	-0.43	-1.47	20.81
2026-10-16	CRSP	-0.50	-1.47	20.81
2026-10-19	CRSP	-0.71	-1.39	20.81
2026-10-20	CRSP	-0.71	-1.39	20.81
2026-10-21	CRSP	-1.39	-1.39	20.81
2026-10-22	CRSP	-1.39	-1.39	20.81
2026-10-23	CRSP	-1.39	-1.39	20.81
2026-10-26	CRSP	-1.39	-1.38	20.81
2026-10-27	CRSP	-1.39	-1.38	18.32
2026-10-28	CRSP	-1.39	-1.38	18.32
2026-10-29	CRSP	-1.39	-1.38	18.32
2026-10-30	CRSP	-1.39	-1.38	18.32
2026-11-02	CRSP	-1.39	-1.47	18.32
2026-11-03	CRSP	-1.39	-1.47	18.32
2026-11-05	CRSP	-1.38	-1.47	18.26
2026-11-06	CRSP	-1.38	-1.47	18.26
2026-11-09	CRSP	-1.38	-1.26	18.26
2026-11-10	CRSP	-1.38	-1.26	18.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.15

Avg. EPS Est. Current Quarter

-1.06

Avg. EPS Est. Next Quarter

-1.09

Insider Transactions

-1.38

Institutional Transactions

-1.26

Beta

1.9

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

50.8

Max Drawdown 5-Year %

-65.7

Target Price

82.74

P/E

Forward P/E

PEG

P/S

174

P/B

2.65

P/Free Cash Flow

EPS

-4.75

Average EPS Est. Cur. Y

-4.54

EPS Next Y. (Est.)

-3.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1812.07

Relative Volume

2.63

Return on Equity vs Sector %

-54

Return on Equity vs Industry %

-34.3

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.09

EBIT Estimation

◆ CRSP Healthcare

$45.15

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

0/15

Valuation

12/20

TP/AR

1/10

Options

5/10

RSI

35.8

Range 1M

2.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

18/25

Growth

18/30

Estimates

0/20

Inst/Vol

3/15

Options

6/10

EPS Yr

30.5%

EPS NY

21.5%

52W%

6.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +83.3% upside

Quality

2/30

Valuation

16/30

Growth

16/25

Stability

6/10

LT Trend

4/5

Upside

+83.3%

Quality

CRSP — P/E HistoricalBiotechnology

CRISPR Therapeutics AG

Sector: Healthcare

Industry: Biotechnology

Employees:

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP

Latest News

—

Caricamento notizie per CRSP…

stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today

news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025

marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance

stock history CRSP – CRISPR Therapeutics AG invest stock market

stock prices CRSP premarket after hours

ticker CRSP fair value insiders trading

CRSP – CRISPR Therapeutics AG

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CRSP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y